Engineered Cell Therapy - Non-Oncology

Chair(s)

• HV

  Hans Dieter Volk

Presentations:

• 1:00 PM – 1:25 PM  

  Enhancing Engineered Treg Therapies
  

  Speaker: Fred Ramsdell – Sonoma Biotherapeutics
• 1:25 PM – 1:40 PM  

  Crispr-mediated Deletion of PD1 to Enhance the Efficacy of Human CAR Tregs
  

  Presenting Author: Dominic A. Boardman, Ph.D. – The University of British Columbia
• 1:40 PM – 2:05 PM  

  Engineering Tcr-tregs for Autoimmune Disease
  

  Speaker: Niranjana Nagarajan, Ph.D. – Abata Therapeutics
• 2:05 PM – 2:20 PM  

  GNTI-122 Is a Stable Engineered Regulatory T Cell Therapy for Type 1 Diabetes That Is Specific, Expandable, and Efficacious in in Vivo Models
  

  Presenting Author: Ashley Landuyt, Ph.D. – GentiBio, Inc
• 2:20 PM – 2:45 PM  

  Rescuing Primary Immundeficiencies by Advanced Genetic Engineering of Hematopoietic Stem Cells and T cells
  

  Speaker: Luigi Naldini, MD, PhD – San Raffaele Telethon Institute for Gene Therapy (SR-Tiget)